Zhichen Sun

List of Publications by Year
in descending order

17 papers	740 citations	623574 14 h-index	839398 18 g-index
19 all docs	19 docs citations	19 times ranked	1193 citing authors

#	Article	IF	Citations
1	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	5.8	132
2	Hepatitis B Virus Induces a Novel Inflammation Network Involving Three Inflammatory Factors, IL-29, IL-8, and Cyclooxygenase-2. Journal of Immunology, 2011, 187, 4844-4860.	0.4	69
3	Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. Journal of Immunology, 2016, 196, 3079-3087.	0.4	69
4	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nature Communications, 2021, 12, 2768.	5.8	62
5	Targeting IFNÎ± to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	5.8	60
6	Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window. Nature Communications, 2020, 11, 5828.	5.8	49
7	Tumorâ€Targeted Inhibition of Monocarboxylate Transporter 1 Improves Tâ€Cell Immunotherapy of Solid Tumors. Advanced Healthcare Materials, 2021, 10, e2000549.	3.9	47
8	Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology, 2017, 66, 1067-1082.	3.6	44
9	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	3.9	38
10	CTLA-4 Limits Anti-CD20â€“Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	3.2	35
11	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nature Biomedical Engineering, 2021, 5, 1261-1273.	11.6	32
12	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€“CD8+ T cells. JCI Insight, 2020, 5, .	2.3	30
13	Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action. Scientific Reports, 2017, 7, 1729.	1.6	29
14	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.2	17
15	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunology Research, 2017, 5, 560-570.	1.6	10
16	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. Scientific Reports, 2018, 8, 17727.	1.6	7
17	T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response. Journal of Virology, 2018, 92, .	1.5	7